Safety of antidiabetes medications: An update

Clinical Pharmacology and Therapeutics

Volumn 98, Issue 2, 2015, Pages 185-195

  Bailey, C J ^a  

^a ASTON UNIVERSITY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDIABETIC AGENT; GLUCOSE; BIOLOGICAL MARKER; GLUCOSE BLOOD LEVEL;

CANCER RISK; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; DRUG ABSORPTION; DRUG COMBINATION; DRUG DISTRIBUTION; DRUG ELIMINATION; DRUG METABOLISM; DRUG SAFETY; FRACTURE; GENITAL TRACT INFECTION; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HUMAN; META ANALYSIS (TOPIC); MONOTHERAPY; NEOPLASM; NON INSULIN DEPENDENT DIABETES MELLITUS; PANCREAS DISEASE; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); POPULATION RESEARCH; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; URINARY TRACT INFECTION; ANIMAL; BLOOD; DIABETES MELLITUS, TYPE 2; DRUG EFFECTS; METABOLISM; PATIENT SAFETY; RISK ASSESSMENT; RISK FACTOR; TIME; TREATMENT OUTCOME;

ANIMALS; BIOLOGICAL MARKERS; BLOOD GLUCOSE; DIABETES MELLITUS, TYPE 2; HUMANS; HYPOGLYCEMIC AGENTS; PATIENT SAFETY; RISK ASSESSMENT; RISK FACTORS; TIME FACTORS; TREATMENT OUTCOME;

EID: 84943352569     PISSN: 00099236     EISSN: 15326535     Source Type: Journal    
DOI: 10.1002/cpt.125     Document Type: Review

References (73)

1. Holman, R.R., Paul, S.K., Bethel, M.A., Matthews, D.R. & Neil, H.A. 10-year follow-up of intensive glucose control in type 2 diabetes. N. Engl. J. Med. 359, 1577-1589 (2008).
2. Bergenstal, R.M., Bailey, C.C. & Kendall, D.M. Type 2 diabetes: assessing the relative risks and benefits of glucose-lowering medications. Am. J. Med. 123, 374.e9-.e18 (2010).
3. Stratton, I.M., et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ. 321, 405-412 (2000).
4. Gerstein, H.C., et al. Effects of intensive glucose lowering in type 2 diabetes. N. Engl. J. Med. 358, 2545-2559 (2008).
5. Patel, A., et al. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N. Engl. J. Med. 358, 2560-2672 (2008).
6. Duckworth, W., et al. Glucose control and vascular complications in veterans with type 2 diabetes. N. Engl. J. Med. 360, 129-139 (2009).
7. American Diabetes Association. Standards of medical care in diabetes-2013. Diabetes Care 36, S11-S66 (2013).
8. Genuth, S. & Ismail-Beigi, F. Clinical implications of the ACCORD trial. J. Clin. Endocrinol. Metab. 97, 41-48 (2012).
9. Ismail-Beigi, F., et al. Individualizing glycemic targets in type 2 diabetes mellitus: implications of recent clinical trials. Ann. Intern. Med. 154, 554-559 (2011).
10. U.S. Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research (CDER). Guidance for Industry: Diabetes Mellitus- Evaluating Cardiovascular Risk in New Antidiabetic Therapies to Treat Type 2 Diabetes.http: //www.fda. gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm071627.pdf>.Accessed November 2013
11. Bailey, C.J. Interpreting adverse signals in diabetes drug development programs. Diabetes Care 36, 2098-2106 (2013).
12. Home, P.D., et al. Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): a multicentre, randomised, open-label trial. Lancet 373, 2125-2135 (2009).
13. US Food and Drug Administration. Endocrinologic and Metabolic Drugs Advisory Committee. (2013). Accessed August 2013. . http: //www.fda.gov/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/EndocrinologicandMetabolicDrugsAdvisoryCommittee/default.htm>
14. Avandia [package insert]. Research Triangle Park, NC: GlaxoSmithKline; 2011
15. European Medicines Agency. European Medicines Agency recommends suspension of Avandia, Avandamet and Avaglim. .http: //www.ema.europa.eu/ema/index.jsp?curl=pages/news-And-events/news/2010/09/news-detail-001119. jsp& murl=menus/news-And-events/news-And-events. jsp& mid=WC0b01ac058004d5c1& jsenabled=true> (2010). Accessed November 2013
16. Erdmann, E., et al. The effect of pioglitazone on recurrent myocardial infarction in 2, 445 patients with type 2 diabetes and previous myocardial infarction: results from the PROactive (PROactive 05) Study. J. Am. Coll. Cardiol. 49, 1772-1780 (2007).
17. Ferrannini, E., et al. High-density lipoprotein-cholesterol and not HbA1c was directly related to cardiovascular outcome in PROactive. Diabetes Obes. Metab. 13, 759-764 (2011).
18. Scirica, B.M., et al. Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus. N. Engl. J. Med. 369, 1317-1326 (2013).
19. White, W.B., et al. Alogliptin after acute coronary syndrome in patients with type 2 diabetes. N. Engl. J. Med. 369, 1327-1335 (2013).
20. MacConell, L., Brown, C., Gurney, K. & Han, J. Safety and tolerability of exenatide twice daily in patients with type 2 diabetes: integrated analysis of 5594 patients from 19 placebo-controlled and comparator-controlled clinical trials. Diabetes Metab. Syndr. Obes. 5, 29-41 (2012).
21. Gerstein, H.C., et al. Basal insulin and cardiovascular and other outcomes in dysglycemia. N. Engl. J. Med. 367, 319-328 (2012).
22. Currie, C.J., Poole, C.D., Evans, M., Peters, J.J. & Morgan, C.L. Mortality and other important diabetes-related outcomes with insulin vs other antihyperglycemic therapies in type 2 diabetes. J. Clin. Endocrinol. Metab. 98, 668-677 (2013).
23. US Food and Drug Administration. Endocrinologic and Metabolic Drugs Advisory Committee.http: //www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeeting-Materials/Drugs/EndocrinologicandMetabolicDrugsAdvisory-Committee/UCM330920. pdf> Accessed September 2013
24. Vigneri, P., Frasca, F., Sciacca, L., Pandini, G. & Vigneri, R. Diabetes and cancer. Endocr. Relat. Cancer. 16, 1103-1123 (2009).
25. Cairns, R.A., Harris, I.I. & Mak, T.W. Regulation of cancer cell metabolism. Nat. Rev. Cancer 11, 85-95 (2011).
26. Home, P. Insulin therapy and cancer. Diabetes Care 36, S240-4 (2013).
27. Currie, C.J., Poole, C.C. & Gale, E.A. The influence of glucoselowering therapies on cancer risk in type 2 diabetes. Diabetologia. 52, 1766-1777 (2009).
28. Jonasson, J.M., et al. Insulin glargine use and short-term incidence of malignancies-A population-based follow-up study in Sweden. Diabetologia. 52, 1745-1754 (2009).
29. Hemkens, L.G., et al. Risk of malignancies in patients with diabetes treated with human insulin or insulin analogues: a cohort study. Diabetologia. 52, 1732-1744 (2009).
30. Colhoun, H.M. Use of insulin glargine and cancer incidence in Scotland: a study from the Scottish Diabetes Research Network Epidemiology Group. Diabetologia. 52, 1755-1765 (2009).
31. Gerstein, H.C. Does insulin therapy promote, reduce, or have a neutral effect on cancers?. JAMA. 303, 446-447 (2010).
32. Smith, U. & Gale, E.A. Does diabetes therapy influence the risk of cancer?. Diabetologia. 52, 1699-1708 (2009).
33. Pollak, M. & Russell-Jones, D. Insulin analogues and cancer risk: cause for concern or cause celebre?. Int. J. Clin. Pract. 64, 628-636 (2010).
34. Giovannucci, E., et al. Diabetes and cancer: a consensus report. Diabetes Care 33, 1674-1685 (2010).
35. FDA Briefing Document: Endocrinologic and Metabolic Drugs Advisory Committee. http: //www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/EndocrinologicandMetabolicDrugsAdvisoryCommittee/UCM390864.pdf>.Accessed 2014
36. Afrezza (insulin human [rDNA origin]) Inhalation Powder: An ultrarapid acting insulin treatment to improve glycemic control in adult patients with diabetes mellitus http: //www.fda.gov/downloads/advisorycommittees/committeesmeetingmaterials/drugs/endocrinologicandmetabolicdrugsadvisorycommittee/ucm390865.pdf>Accessed 2014
37. Bjerre Knudsen, L., et al. Glucagon-like peptide-1 receptor agonists activate rodent thyroid C-cells causing calcitonin release and C-cell proliferation. Endocrinology 151, 1473-1486 (2010).
38. Hegedus, L., Moses, A.C., Zdravkovic, M., Le Thi, T. & Daniels, G.H. GLP-1 and calcitonin concentration in humans: lack of evidence of calcitonin release from sequential screening in over 5000 subjects with type 2 diabetes or nondiabetic obese subjects treated with the human GLP-1 analog, liraglutide. J. Clin. Endocrinol. Metab. 96, 853-860 (2011).
39. Victoza [package insert]. Bagsvaerd, Denmark: Novo Nordisk A/S; 2011
40. Bydureon [package insert]. San Diego, CA: Amylin Pharmaceuticals, LLC; 2012
41. Lewis, J.D., et al. Risk of bladder cancer among diabetic patients treated with pioglitazone: interim report of a longitudinal cohort study. Diabetes Care 34, 916-922 (2011).
42. National Cancer Institute. Surveillance Epidemiology and End Results (SEER) Fast Stats. http: //seer.cancer.gov/faststats/>. Accessed November 2013
43. European Medicines Agency. Forxiga (dapagliflozin). http: //www.ema. europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/002322/human-med-001546.jsp& mid=WC0b01ac058001d124>. Accessed February 2014
44. Farxiga [package insert]. Wilmington, DE: AstraZeneca Pharmaceuticals LP; 2014
45. Butler, P.C., Elashoff, M., Elashoff, R. & Gale, E.A. A critical analysis of the clinical use of incretin-based therapies: are the GLP-1 therapies safe?. Diabetes Care 36, 2118-2125 (2013).
46. Nauck, M.A. A critical analysis of the clinical use of incretin-based therapies: The benefits by far outweigh the potential risks. Diabetes Care 36, 2126-2132 (2013).
47. Matveyenko, A.V., et al. Beneficial endocrine but adverse exocrine effects of sitagliptin in the human islet amyloid polypeptide transgenic rat model of type 2 diabetes: interactions with metformin. Diabetes 58, 1604-1615 (2009).
48. Nachnani, J.S., et al. Biochemical and histological effects of exendin-4 (exenatide) on the rat pancreas. Diabetologia. 53, 153-159 (2010).
49. Gier, B., et al. Chronic GLP-1 receptor activation by exendin-4 induces expansion of pancreatic duct glands in rats and accelerates formation of dysplastic lesions and chronic pancreatitis in the Kras(G12D) mouse model. Diabetes 61, 1250-1262 (2012).
50. Nyborg, N.C., Molck, A.M., Madsen, L.L. & Knudsen, L.B. The human GLP-1 analog liraglutide and the pancreas: evidence for the absence of structural pancreatic changes in three species. Diabetes 61, 1243-1249 (2012).
51. Tatarkiewicz, K., et al. Exenatide does not evoke pancreatitis and attenuates chemically induced pancreatitis in normal and diabetic rodents. Am. J. Physiol. Endocrinol. Metab. 299, E1076-1086 (2010).
52. Koehler, J.A., Baggio, L.L., Lamont, B.J., Ali, S. & Drucker, D.J. Glucagon-like peptide-1 receptor activation modulates pancreatitisassociated gene expression but does not modify the susceptibility to experimental pancreatitis in mice. Diabetes 58, 2148-2161 (2009).
53. Elashoff, M., Matveyenko, A.V., Gier, B., Elashoff, R. & Butler, P.C. Pancreatitis, pancreatic, and thyroid cancer with glucagon-like peptide-1-based therapies. Gastroenterology 141, 150-156 (2011).
54. Nauck, M.M & Friedrich, N. Do GLP-1-based therapies increase cancer risk?. Diabetes Care 36, S245-252 (2013).
55. Drucker, D.J., Sherman, S.I., Bergenstal, R.R. & Buse, J.B. The safety of incretin-based therapies-review of the scientific evidence. J. Clin. Endocrinol. Metab. 96, 2027-2031 (2011).
56. Dore, D.D., Seeger, J.J. & Chan, K.A. Use of a claims-based active drug safety surveillance system to assess the risk of acute pancreatitis with exenatide or sitagliptin compared to metformin or glyburide. Curr. Med. Res. Opin. 25, 1019-1027 (2009).
57. Butler, A.E., et al. Marked expansion of exocrine and endocrine pancreas with incretin therapy in humans with increased exocrine pancreas dysplasia and the potential for glucagon-producing neuroendocrine tumors. Diabetes 62, 2595-2604 (2013).
58. Harja, E., Lord, J. & Skyler, J.S. An analysis of characteristics of subjects examined for incretin effects on pancreatic pathology. Diabetes Technol. Ther. 15, 609-618 (2013).
59. Habib, Z.A., et al. Thiazolidinedione use and the longitudinal risk of fractures in patients with type 2 diabetes mellitus. J. Clin. Endocrinol. Metab. 95, 592-600 (2010).
60. Loke, Y.K., Singh, S. & Furberg, C.D. Long-term use of thiazolidinediones and fractures in type 2 diabetes: a meta-Analysis. CMAJ. 180, 32-39 (2009).
61. Hampton, T. Diabetes drugs tied to fractures in women. JAMA. 297, 1645 (2007).
62. Riche, D.D. & King, S.T. Bone loss and fracture risk associated with thiazolidinedione therapy. Pharmacotherapy 30, 716-727 (2010).
63. Tahrani, A.A., Bailey, C.J., Del Prato, S. & Barnett, A.H. Management of type 2 diabetes: new and future developments in treatment. Lancet 378, 182-197 (2011).
64. Zhang, M., et al. Dapagliflozin treatment for type 2 diabetes: a systematic review and meta-Analysis of randomized controlled trials. Diabetes Metab. Res. Rev. 2013
65. Invokana [package insert]. Titusvill, NJ: Janssen Ortho, LLC; 2013
66. Kendall, D.M., Cuddihy, R.R. & Bergenstal, R.M. Clinical application of incretin-based therapy: therapeutic potential, patient selection and clinical use. Eur. J. Intern. Med. 20, S329-339 (2009).
67. Inzucchi, S.E., et al. Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care 35, 1364-1379 (2012).
68. DeFronzo, R.A. Banting Lecture. From the triumvirate to the ominous octet: a new paradigm for the treatment of type 2 diabetes mellitus. Diabetes 58, 773-795 (2009).
69. DeFronzo, R.A., Eldor, R. & Abdul-Ghani, M. Pathophysiologic approach to therapy in patients with newly diagnosed type 2 diabetes. Diabetes Care 36, S127-138 (2013).
70. A Comparative Effectiveness Study of Major Glycemia-lowering Medications for Treatment of Type 2 Diabetes (GRADE). http: //clinicaltrials.gov/ct2/show/NCT01794143?term=GRADE& rank=1>. Accessed November 2013
71. Bailey, C.C. & Feher, M.D. Diabetes Therapies: Treating Hyperglycemia. Coombs Wood Center, UK: MedED UK Ltd; 2009
72. Bonds, D.E., et al. The association between symptomatic, severe hypoglycaemia and mortality in type 2 diabetes: retrospective epidemiological analysis of the ACCORD study. BMJ. 339, b4909 (2010).
73. Zoungas, S., et al. Severe hypoglycemia and risks of vascular events and death. N. Engl. J. Med. 363, 1410-1418 (2010).